TW201338810A - Microcapsule structure having conditioned medium of mesenchymal stem cells and the functions of promoting the regeneration of epidermal cells, angiogenesis and the damage repair for the epidermal cells and method for manufacturing the same - Google Patents

Abstract

The invention relates to a microcapsule structure having conditioned medium of mesenchymal stem cells and the functions of promoting the regeneration of epidermal cells, angiogenesis and the damage repair for the epidermal cells and a method for manufacturing the same. The microcapsule structure comprises at least one conditioned medium of mesenchymal stem cells and a capsule body, wherein the capsule body consists of a low temperature dissolved wax, shown as a hollow shape and formed a receiving space to receive the conditioned medium of mesenchymal stem cells to avoid the deterioration of the active ingredient contained in the conditioned medium of mesenchymal stem cells. Accordingly, the microcapsule structure can be applied to promote the repair for the lung damage, corneal damage, skin wounds, liver damage, kidney damage and osteoporosis or skin care.

Description

Microcapsule structure with stem cell conditioned medium promoting epidermal cell regeneration, angiogenesis and epidermal cell damage repair function and preparation method thereof

The present invention relates to a microcapsule structure having a stem cell conditioned medium for promoting epidermal cell regeneration, angiogenesis and epidermal cell damage repair function, in particular, the inclusion of a substance capable of promoting epidermal cell regeneration, angiogenesis and epidermal cell damage repairing ability. A cystic microcapsule structure of a cytokine conditioned medium; thereby, it can be applied to promote lung damage, corneal damage, skin wounds, liver damage, kidney damage, and repair of osteoporosis or skin care.

According to the daily life, whether it is due to internal factors or external factors, the human body often suffers from different injuries, such as skin aging, skin wounds, lung damage, corneal damage, liver damage, kidney damage or osteoporosis. . The accumulation and aggravation of different injuries ultimately leads to a decline in people's health and quality of life.

Causes of skin aging include external factors (sun exposure, pollution, free radical damage, smoking) and intrinsic factors (natural cell death, natural aging, reduced hormones, decreased immunity), which in turn causes skin dullness and wrinkles and spots. Causes of skin wounds include surgery, trauma, or necrosis and necrosis of cells caused by compression of local skin and soft tissues underneath for a long time. Causes of lung damage (referred to here as lung damage refers to damage to the epidermal cells of the lungs) Possible causes include: blood transfusion, disease, overuse (eg, hyperventilation) or inhalation of harmful substances (eg chlorine in swimming pools, cigarettes) Containing nicotine with tar or dust), which causes chest pain, Symptoms of difficulty breathing, shortness of breath, hemoptysis, and infection can cause impaired lung function over a long period of time; current treatments for lung injury include surgery and respiratory therapy. Possible causes of corneal damage (herein referred to as corneal damage refers to damage to corneal epithelial cells) include over-eye, itching, wearing contact lenses or UV rays, resulting in tearing, unclear sight, pain and foreign body sensation, etc. Symptoms, which can lead to blindness in severe conditions; current treatments for corneal damage include: medical treatment, laser surgery, and corneal transplantation. Possible causes of liver damage include acute liver damage caused by drugs, liver damage caused by viral (such as hepatitis virus), alcoholic liver damage, fatty liver caused by improper eating habits, and decreased liver function caused by day and night fatigue Or liver damage caused by environmental pollution, which can cause liver failure and even liver transplantation in severe cases. Kidney damage occurs in the elderly, patients with vascular disease (eg, hypertension), patients with chronic diseases (eg, diabetic patients), those who use large amounts of drugs (eg, patients with rheumatoid arthritis and chemotherapy), Patients after surgery or after major trauma (eg maternal) or those who take poison, the symptoms include reduced urine output, discomfort, nausea and vomiting, lower extremity edema and rapid decline in glomerular filtration rate, and kidney transplantation in severe cases. . Osteoporosis is a phenomenon of mineral loss caused by the movement of calcium from the bones to the blood, which leads to a decrease in bone mass, an increase in bone porosity, and a hollowing out of bones. The rate of osteoporosis depends on osteoclasts and osteogenesis. The growth and decline of cell activity. Risk factors for osteoporosis include: gender (especially female), premature menopause, ethnicity (especially whites and Asians), thin bone structure, low body mass index, smoking, alcohol abuse, insufficient activity, family History; current practice is recommended for women with menopause to supplement estrogen or for the general population to increase the intake of calcium and vitamin D3 in the diet to slow the occurrence of osteoporosis. The reason for the above-mentioned different damages is unavoidable in the people of today's world.

Literature studies have shown that stem cells can promote epidermal cell regeneration, angiogenesis and epidermal cell damage repair by secreting growth factors. The above-mentioned skin aging, skin wounds, lung damage, corneal damage, liver damage, kidney damage or osteoporosis can be improved by stem cell transplantation therapy. Among them, osteoporosis can be improved by promoting the angiogenesis of stem cells to increase the supply of bone nutrients. However, the disadvantage of stem cell transplantation is that it is still experimental and invasive, and is not currently widely practiced; however, stem cell culture media is used as an alternative to providing a source of growth factors. Process of commercialization of growth factors In the face of long-term storage, which causes the deterioration of the active ingredient, it is important to develop a structure for the preservation of the growth factor in the commodity; in addition, the damage is generally caused by the user who does not have the symptoms of the above-mentioned damage, not the patient. To the extent that treatment is not required, and only those who want to be improved by daily maintenance are more important, the convenience of using the product with damage repair ability is more important; for this reason, a medium with stem cell conditions is proposed to promote epidermal cell regeneration and blood vessels. The microcapsule structure of the repair function of newborn and epidermal cells has its industrial applicability. The inventors therefore developed a microcapsule structure with stem cell conditioned medium to promote epidermal cell regeneration, angiogenesis and epidermal cell damage repair function, thereby promoting lung injury, corneal damage, skin wounds, liver damage, kidney damage and bone mass. Loose repair or skin care (for the application of lung injury and corneal damage repair, please refer to another patent application filed on the equivalent date of the inventor, "Microcapsule structure with stem cell conditioned medium combination solution", and skin wound repair and skin care For the application, please refer to another patent application "Microcapsule dressing with stem cell conditioned medium combination solution" filed by the inventor.

Now, the inventor is currently lacking a structural product containing mesenchymal stem cell conditioned medium that can be applied to promote lung damage, corneal damage, skin wounds, liver damage, kidney damage, and osteoporosis repair or skin maintenance applications. Therefore, it is a tireless spirit, and it is improved by its rich professional knowledge and years of practical experience, and the invention is developed accordingly.

The main object of the present invention is to provide a microcapsule structure having a stem cell conditioned medium for promoting epidermal cell regeneration, angiogenesis and epidermal cell damage repair function, wherein a capsule encapsulated by a low temperature dissolving wax promotes epidermal cell regeneration, angiogenesis and Epidermal Cell Damage Repair One of the mesenchymal stem cell conditioned media forms a microcapsule structure for use in promoting lung damage, corneal damage, skin wounds, liver damage, kidney damage, and osteoporosis repair or skin care.

In order to achieve the above-mentioned object, the present inventors have developed a microcapsule structure containing a mesenchymal stem cell conditioned medium comprising at least one mesenchymal stem cell conditioned medium and a capsule for containing the mesenchymal stem cell conditioned medium.

Furthermore, the present invention further provides a microgel containing a mesenchymal stem cell conditioned medium. The method for manufacturing a capsule structure comprises the steps of at least one step of: culturing mesenchymal stem cells; step two: collecting mesenchymal stem cell conditioned medium; and step three: heating the low temperature dissolving wax and mixing the mesenchymal stem cell conditioned medium to prepare the medium. Microcapsule structure of cytokine conditioned medium.

In an embodiment of the invention, the capsule may be composed, for example, of a low temperature dissolving wax; wherein the low temperature dissolving wax may have a melting point between 35 ° C and 45 ° C.

In an embodiment of the present invention, the source of the mesenchymal stem cell conditioned medium may be, for example, a primary culture interstitial stem cell or a commercially available mesenchymal stem cell strain; wherein the commercially available mesenchymal stem cell strain is, for example, Watson's coagulation In the case of Wharton's jelly mesenchymal stem cells (WJ-MSC), a conditioned medium for human foreskin fibroblast culture can be further added.

In an embodiment of the present invention, the mesenchymal stem cell conditioned medium may further be added with glycerin, vitamin C glycoside, human oligopeptide-1, human oligopeptide-3, human oligopeptide-6 or pure water. One.

In an embodiment of the invention, the microcapsule structure and a diluent may be further disposed in a stereo spray bottle for the user to directly spray on the throat or the cornea to promote lung damage or corneal damage repair. .

In an embodiment of the invention, the microcapsule structure can be further disposed in a dressing for repair of skin wounds or skin care.

In an embodiment of the invention, the microcapsule structure can be further disposed in a health food for direct consumption by a user to promote liver damage, kidney damage, and repair of osteoporosis.

Thereby, the microcapsule structure is arranged to avoid deterioration of the active ingredient contained in the mesenchymal stem cell conditioned medium; in addition, the mesenchymal stem cell conditioned medium can promote epidermal cell regeneration, angiogenesis and epidermal cell damage repair, and further apply Promotes lung damage, corneal damage, skin wounds, liver damage, kidney damage, and osteoporosis repair or skin care.

(1) ‧‧‧ capsule

(2) ‧‧‧ accommodating space

(3) ‧ ‧ stromal stem cell conditioned medium

First: Schematic diagram of the microcapsule structure of the preferred embodiment of the present invention

Second: Flow chart of the manufacturing method of the microcapsule structure of the present invention

Figure 3: Effect of mesenchymal stem cell conditioned medium on ischemic status of hind limbs in mice

Figure 4 (A): Image analysis of the effect of mesenchymal stem cell conditioned medium on ischemic status of hind limbs in mice by laser Doppler flow imaging

Figure 4 (B): Quantitative analysis of the effect of mesenchymal stem cell conditioned medium on ischemic status of hind limbs in mice by laser Doppler flow imaging

Figure 5 (A): Image of hematoxylin-eosin staining results of histological analysis of the recovery of the adductor muscle at 28 days

Figure 5 (B): Quantitative map of hematoxylin-eosin staining results for histological analysis of adductor recovery at 28 days

Figure 6 (A): Image of the results of the Masson trichrome staining results of histological analysis of the recovery of the adductor muscle at 28 days

Figure 6 (B): Quantitative map of the results of the Masson trichrome staining of histological analysis of the recovery of the adductor muscle at 28 days

Figure 7 (A): Image of CD31 immunostaining results of histological analysis of the recovery of the adductor muscle at 28 days

Figure 7 (B): Quantitative map of CD31 immunostaining results for histological analysis of the recovery of the adductor muscle at 28 days

The object of the present invention and its structural design and advantages will be explained in the light of the preferred embodiments shown in the following drawings, so that the reviewing committee can have a more in-depth and specific understanding of the present invention.

First, please refer to the first figure, which is a schematic diagram of the microcapsule structure of the preferred embodiment. The microcapsule structure of the present invention comprises at least one mesenchymal stem cell conditioned medium (3) and a capsule (1). The mesenchymal stem cell conditioned medium (3) can promote epidermal cell regeneration, angiogenesis and epidermal cell damage repair; the capsule (1) can be composed of low temperature dissolved wax, wherein the capsule (1) is hollow and formed. A housing space (2) can accommodate the mesenchymal stem cell conditioned medium (3); the microcapsule structure can be used to avoid deterioration of the active ingredient contained in the mesenchymal stem cell conditioned medium (3).

Furthermore, please refer to the second figure, which is a flow chart of the manufacturing method of the microcapsule structure of the present invention, and the manufacturing method thereof comprises at least: Step 1: culturing mesenchymal stem cells; wherein the mesenchymal stem cells may be primary cultured mesenchymal stem cells or commercially available mesenchymal stem cell lines; Step 2: collecting mesenchymal stem cell conditioned medium (3); wherein the commercially available mesenchymal stem cell strain is When the Wharton gel interstitial stem cells are used, a conditioned medium for human foreskin fibroblast culture may be further added; and step 3: heating the low temperature dissolving wax and mixing the mesenchymal stem cell conditioned medium (3) to prepare a conditioned medium containing mesenchymal stem cells. (3) Microcapsule structure.

The microcapsule structure between the conditioned medium (3) can further add one of glycerin, vitamin C glycoside, human oligopeptide-1, human oligopeptide-3, human oligopeptide-6 or pure water; The capsule structure and a diluent can be further disposed in a three-dimensional spray bottle for the user to directly spray on the throat or the cornea to promote lung damage or corneal damage repair; in addition, the microcapsule structure can be further integrated into one The dressing is for the repair of skin wounds or skin care; and the microcapsule structure can be further set into a health food for direct consumption by the user to promote liver damage, kidney damage and repair of osteoporosis.

Several embodiments are utilized below to illustrate the application of the present invention. In the first embodiment, the primary cultured mesenchymal stem cells were used as the source of mesenchymal stem cell conditioned medium (3), and the effect of mesenchymal stem cell conditioned medium (3) on angiogenesis was analyzed by limb ischemia model. The second embodiment is based on the premise that the stem cell source is safe to the user in the actual implementation of the present invention, and the commercially available Wharton gel mesenchymal stem cell cell line is not the primary cultured mesenchymal stem cell as the mesenchymal stem cell. Conditioned medium (3) source. It is not intended to limit the invention, and various modifications and changes may be made without departing from the spirit and scope of the invention.

Example 1: Effect of Mesenchymal Stem Cell Conditioned Medium on Angiogenesis 1. Cell culture

Primary cultured mesenchymal stem cells were grown in complete growth medium (CCM) (α-MEM medium (purchased from Gibco) containing 10% fetal bovine serum, 100 units/ml penicillin and 10 μg/ml streptomycin) The culture was carried out at a temperature of 37 ° C and containing 5% carbon dioxide. The cells are recovered by centrifugation and replaced when the number of cells reaches 100 cells/cm 2 The cell culture dish was cultured in CCM and the medium was changed every 2-3 days. Subcultured cells are recovered for about 8-9 days when the cells grow to a level that is 80% of the growth plane.

2. Preparation of mesenchymal stem cell conditioned medium

Mesenchymal stem cells were placed in a cell culture dish at a rate of 5000 cells/cm 2 and in CCM for one day. Every two days after the interval, the attached cells were washed three times with phosphate buffer, and the CCM was replaced with α-MEM medium containing no fetal bovine serum to produce primary cultured interstitial stem cell conditioned medium (3). The mesenchymal stem cell conditioned medium (3) was collected for 48 hours, and the mesenchymal stem cell conditioned medium (3) was separated by passing at 2000 rpm for 10 minutes and passed through a 0.3 μm filter. The mesenchymal stem cell conditioned medium (3) was concentrated to 20 times the initial concentration with Vivaspin 20 (cut-off 3KDa, available from GE Health care UK Ltd., Buckinghamshire, UK). The concentrated interstitial stem cell conditioned medium (3) was stored frozen at -80 ° C until use.

3. Limb ischemia model

The method of animal testing was reviewed and approved by the Animal Care and Use Committee of National Taiwan University Hospital. Six-week-old male Balb/C mice were used in this experiment. The study complies with the guidelines for laboratory care and use published by the National Institutes of Health. General anesthesia was performed using 10 mg/kg xylazine and 10 mg/kg ketamine, and a skin incision was made to the knee of the mouse thigh. After the subcutaneous fat tissue was cut, the femoral artery near the proximal position of the iliac crest was exposed. The femoral artery was then double-twisted in the middle of the thigh, and the 5 mm-length femoral artery was excised. On days 1, 8, 15, and 22 after arterial resection, 50 μl of 20-fold mesenchymal stem cell conditioned medium (3) or α-MEM was intramuscularly injected into the gracilis muscle near the resection site. Male Balb/C mice were sacrificed on day 28 using cervical dislocation. Data from the laser Doppler flow imager are expressed as mean ± standard deviation. All data were analyzed by one of the Bonferroni post-hoc test 2-way A NOVA. P < 0.05 was considered as a significant difference.

4. Assessment of blood flow reperfusion

Laser Doppler flow imaging is used for a series of non-invasive physiological assessments of neovascularization. A series of blood flow scans on the hind limb surface (including the first, seventh, and fourth after treatment, 21 and 28 days) The physiological condition of the mice was monitored. Digital color image coding was analyzed to quantify blood flow from the thigh to toe region, and the average value of reperfusion was calculated.

5. Experimental result

The following experiment is an analysis of the effect of mesenchymal stem cell conditioned medium (3) on angiogenesis. The α-MEM indicated in the figure is the control group, and the conditioned medium (3) of the stem cell between the experimental groups is indicated as primary (the cell source is the primary cultured stem cells). In the model of hind limb ischemia mice, the improvement of mesenchymal stem cell conditioned medium (3) and α-MEM directly into the adductor muscles (ie, the lateral limb vascular remodeling area) was compared to the hindlimb ischemia status. The results showed that the mesenchymal stem cell conditioned medium (3) has the function of lateral limb vascular remodeling in the limb ischemia model. As shown in the third figure, it is the effect of mesenchymal stem cell conditioned medium on the hindlimb ischemia status of mice. In the control group (ie, α-MEM injection), 80% of the mice (8 out of 10 mice) Only mice) suffered from limb loss, while 20% of mice (2 out of all 10 mice) had foot necrosis. However, patients receiving mesenchymal stem cell conditioned medium (3) had no hind limb defect and the limb salvage rate was 50%. As shown in the fourth figure, the effect of mesenchymal stem cell conditioned medium on the ischemic condition of hind limbs in mice was analyzed by laser Doppler flow imaging. The fourth images (A) and (B) are image and quantitative maps, respectively. Laser Doppler flow imaging analysis showed that after 28 days, the control group injection (ie, α-MEM) was only 40% of the ischemic hind limbs with LDPI of flow rate. Blood flow. However, those who received mesenchymal stem cell conditioned medium (3) had a significantly improved blood flow improvement compared with those who received the control group (i.e., injected with α-MEM). As shown in the fifth figure, the results of hematoxylin-eosin staining were analyzed by histological analysis of the recovery of the adductor muscle at 28 days, and the fifth images (A) and (B) were image and quantitative maps, respectively. Hematoxylin-eosin (H&E) staining showed an increase in muscle size of the ischemic hind limbs injected with mesenchymal stem cell conditioned medium (3) compared with the control group. As shown in the sixth figure, the results are the results of the Masson trichrome staining of the histological analysis of the recovery of the adductor muscle at 28 days, and the sixth images (A) and (B) are the image and quantitative maps, respectively. Masson’s trichrome staining results showed that the conditioned medium (3) receiving mesenchymal stem cells was injected more than the control group. The proportion of areas of muscle necrosis in the ischemic hind limbs decreased. As shown in the seventh figure, the results of CD31 immunostaining were analyzed by histological analysis of the recovery of the adductor muscle at 28 days, and the seventh images (A) and (B) were image and quantitative maps, respectively. The results of immunostaining with CD31 showed that the density of epidermal cells was increased in the conditioned medium (3) injected with mesenchymal stem cells compared with the ischemic hind limbs injected into the control group. The above results confirmed that the mesenchymal stem cell conditioned medium (3) has a function of promoting epidermal cell regeneration, angiogenesis, and epidermal cell damage repair.

Example 2: Manufacturing of microcapsule structure

First, Watson's gel mesenchymal stem cells were used as the source of mesenchymal stem cell conditioned medium (3). Watson's gel mesenchymal stem cells were grown in CCM (α-MEM medium (purchased from Gibco) containing 10% fetal bovine serum, 100 units/ml penicillin and 10 μg/ml streptomycin) at a temperature of 37 ° C and containing 5 Cultivate in a carbon dioxide environment. The cells were recovered by centrifugation and the cell culture dishes were replaced when the number of cells reached 100 cells/cm 2 , cultured in CCM and the medium was changed every 2-3 days. Subcultured cells are recovered for about 8-9 days when the cells grow to a level that is 80% of the growth plane. Next, Watson's gel mesenchymal stem cells were placed in a cell culture dish at a ratio of 5000 cells/cm 2 and cultured in CCM for one day. Every two days after the interval, the attached cells were washed three times with phosphate buffer, and the medium was replaced with α-MEM medium containing no fetal bovine serum to produce a stem cell conditioned medium between Watson's gel mesenchymal stem cells (3) . The culture medium was collected for 48 hours, and the conditioned medium was separated by a rpm of 2000 rpm for 10 minutes and passed through a 0.3 μm filter. The mesenchymal stem cell conditioned medium (3) was concentrated with Vivaspin 20 to 20 times the initial concentration. The concentrated interstitial stem cell conditioned medium (3) was stored frozen at -80 ° C until use. The conventional centrifugation and filtration step can achieve the purpose of collecting the mesenchymal stem cell conditioned medium (3). Therefore, the mesenchymal stem cell conditioned medium (3) can be brought to a desired concentration by concentration in a concentrated manner. The literature indicates that the conditioned medium (3) of the stem cell culture of Wharton's interphase mesenchymal stem cells contains various human growth factors, including epidermal growth factor (EGF), basic fibroblast growth factor (b-FGF) and skin stem cells. Growth factor (SCF) is involved in the repair and regeneration of epidermal cells; in which epidermal growth factor binds to the epidermal growth factor receptor (EGFR) of the basal cell membrane of the epidermis, it accelerates epidermal cell division; while basic fibroblast growth factor has Assist in angiogenesis (angi (ogenesis), the function of wound healing, and at the same time has the function of fibroblast, which stimulates fibroblasts to activate fibroblasts; in addition, skin stem cell growth factor mainly acts to induce basal stem cells Hyperplasia; however, the relative amount of basic fibroblast growth factor in the conditioned medium (3) of Wharton's mesenchymal stem cell culture is relatively small, so it can be grown by adding more basic fibroblasts. The conditioned medium of the factor human human foreskin fibroblast culture is supplemented. Thereafter, heating the low temperature dissolving wax and mixing the mesenchymal stem cell conditioned medium (3) to prepare a microcapsule structure containing the mesenchymal stem cell conditioned medium (3); wherein the melting point of the low temperature dissolving wax is between 35 ° C and 45 ° C; Heating the low-temperature dissolving wax to a temperature higher than the melting point of the low-temperature dissolving wax, but not denaturing the active ingredient of the mesenchymal stem cell conditioned medium (3), and then uniformly mixing the mesenchymal stem cell conditioned medium (3) with the low-temperature dissolving wax to achieve The effect of hydration is to form a lipid particle type capsule (1) by hydrophobic action to form a lipid granule type capsule (1) to encapsulate the mesenchymal stem cell conditioned medium (3). The shape of the lipid particle (for example, the structure of the single layer film, the double layer film or the multilayer film) and the size can be further changed by shaking or extrusion according to actual needs to obtain the structure of the microcapsule. The structure of the microcapsules is freeze dried to remove moisture for storage and shipping. By setting the microcapsule structure, deterioration of the active ingredient contained in the mesenchymal stem cell conditioned medium (3) can be avoided.

Further, one of glycerol, vitamin C glycoside, human oligopeptide-1, human oligopeptide-3, human oligopeptide-6 or pure water may be further added to the mesenchymal stem cell conditioned medium (3) according to actual needs; Among them, glycerin can increase the moisturization of epidermal cells; vitamin C glycoside vitamin C followed by two glucose molecule inducers, not only has its strong reducing power and antioxidant effect, but also has better stability. And human oligopeptide-1 (commonly known as epidermal growth factor), human oligopeptide-3 (commonly known as basic fibroblast growth factor) and human oligopeptide-6 (commonly known as skin stem cell growth factor) It can complement and enhance the effect of a single component.

It is worth noting that the temperature at which the microcapsule structure is prepared is adjusted according to the type of low-temperature dissolving wax; and the mesenchymal stem cell conditioned medium (3), glycerol, vitamin C glycoside, human oligopeptide-1, human oligopeptide- 3. The ratio of human oligopeptide-6 and pure water can be adjusted according to the use of the microcapsule structure and the effect to be achieved; otherwise, it is not limited by this example. The principle of the invention can be applied to any microcapsule structure containing mesenchymal stem cell conditioned medium (3), its manufacturing method and its application.

The microcapsule structure and the implementation description of promoting the epidermal cell regeneration, angiogenesis and epidermal cell damage repair function by the above-described stem cell conditioned medium have the following advantages:

1. The present invention prevents the deterioration of the active ingredient contained in the conditioned medium of the mesenchymal stem cells by the arrangement of the microcapsule structure.

2. The present invention promotes epidermal cell regeneration, angiogenesis and epidermal cell damage repair by mesenchymal stem cell conditioned medium, and is then used to promote lung damage, corneal damage, skin wounds, liver damage, kidney damage, and repair of osteoporosis or Skin care use.

3. The present invention can be further applied to different uses by the arrangement of the microcapsule structure and is convenient for the user's daily use.

In summary, the microcapsule structure of the present invention having a stem cell conditioned medium for promoting epidermal cell regeneration, angiogenesis, and epidermal cell damage repair function can achieve the intended efficacy by the above disclosed embodiments, and The present invention has not been disclosed before the application, and Cheng has fully complied with the requirements and requirements of the Patent Law.爰Issuing an application for a patent for invention in accordance with the law, and asking for a review, and granting a patent, is truly sensible.

The illustrations and descriptions of the present invention are merely preferred embodiments of the present invention, and are not intended to limit the scope of the present invention; those skilled in the art, which are characterized by the scope of the present invention, Equivalent variations or modifications are considered to be within the scope of the design of the invention.

(1) ‧‧‧ capsule

(2) ‧‧‧ accommodating space

(3) ‧ ‧ stromal stem cell conditioned medium

Claims (10)

The invention relates to a microcapsule structure having a stem cell conditioned medium for promoting epidermal cell regeneration, angiogenesis and epidermal cell damage repair function, which comprises at least: a mesenchymal stem cell conditioned medium: promoting epidermal cell regeneration, angiogenesis and epidermal cell damage repair; The capsule is composed of a low-temperature dissolving wax, wherein the capsule system is hollow and forms an accommodation space for accommodating the mesenchymal stem cell conditioned medium to avoid deterioration of the active ingredient contained in the mesenchymal stem cell conditioned medium. The microcapsule structure of claim 1, wherein the capsule system is composed of a low temperature dissolving wax, and the melting point of the low temperature dissolving wax is between 35 ° C and 45 ° C. The microcapsule structure according to claim 1, wherein the mesenchymal stem cell conditioned medium is derived from a primary culture between a stem cell or a commercially available mesenchymal stem cell line. The microcapsule structure according to claim 3, wherein the commercially available mesenchymal stem cell line is a Wharton gel mesenchymal stem cell. The conditioned medium for human foreskin fibroblast culture is further added as in the microcapsule structure described in claim 4 of the patent application. The microcapsule structure according to claim 1, wherein the mesenchymal stem cell conditioned medium further comprises glycerin, vitamin C glycoside, human oligopeptide-1, human oligopeptide-3, human oligopeptide-6 or One of pure water. The microcapsule structure according to claim 1, wherein the microcapsule structure and the diluent system are further disposed in a three-dimensional spray bottle for the user to directly spray on the throat or the cornea to promote lung injury. Or repair of corneal damage. The microcapsule structure according to claim 1, wherein the microcapsule structure is further disposed in a dressing for repairing skin care or skin care. The microcapsule structure according to claim 1, wherein the microcapsule structure is further disposed in a health food for direct consumption by a user to promote liver damage, kidney damage, and repair of osteoporosis. A method for producing a microcapsule structure having a stem cell conditioned medium comprises at least: step 1: culturing mesenchymal stem cells; step 2: collecting mesenchymal stem cell conditioned medium; and step 3: heating a low temperature dissolving wax and mixing the interstitial Stem cell conditioned medium to prepare a microcapsule structure containing the mesenchymal stem cell conditioned medium.